Investor Firms Court Nektar Holders Ahead of May 5 Lead‑Plaintiff Deadline
Plaintiffs allege Nektar hid enrollment violations in its REZOLVE‑AA alopecia study that skewed results.
Overview
- Rosen Law Firm and Glancy Prongay Wolke & Rotter are urging Nektar investors to seek lead‑plaintiff status before the May 5, 2026 deadline.
- The complaint alleges the REZOLVE‑AA trial enrolled ineligible patients and failed to follow protocol, which likely hurt the study’s results.
- Plaintiffs say Nektar overstated the trial’s integrity and misled investors during the February 26 to December 15, 2025 class period.
- Investor notices emphasize that no class has been certified and that investors are not represented unless they retain counsel or a class is certified.
- The lawsuit ties investor losses to Nektar’s later disclosure that the Phase 2b study missed statistical significance and included ineligible patients.